MA53817A - Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv - Google Patents

Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv

Info

Publication number
MA53817A
MA53817A MA053817A MA53817A MA53817A MA 53817 A MA53817 A MA 53817A MA 053817 A MA053817 A MA 053817A MA 53817 A MA53817 A MA 53817A MA 53817 A MA53817 A MA 53817A
Authority
MA
Morocco
Prior art keywords
biphenyl
treatment
type
sulfonamide compounds
collagen diseases
Prior art date
Application number
MA053817A
Other languages
English (en)
Inventor
Celia Jenkinson
Radko Komers
Original Assignee
Travere Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68318947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA53817(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Travere Therapeutics Inc filed Critical Travere Therapeutics Inc
Publication of MA53817A publication Critical patent/MA53817A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MA053817A 2018-10-04 2019-10-03 Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv MA53817A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862741270P 2018-10-04 2018-10-04
US201962853904P 2019-05-29 2019-05-29
US201962894559P 2019-08-30 2019-08-30

Publications (1)

Publication Number Publication Date
MA53817A true MA53817A (fr) 2021-08-11

Family

ID=68318947

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053817A MA53817A (fr) 2018-10-04 2019-10-03 Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv

Country Status (13)

Country Link
US (1) US11207299B2 (fr)
EP (1) EP3860594B1 (fr)
JP (2) JP7524167B2 (fr)
KR (1) KR102902972B1 (fr)
CN (1) CN113286587A (fr)
AU (1) AU2019354784B2 (fr)
BR (1) BR112021006132A2 (fr)
CA (1) CA3114434A1 (fr)
ES (1) ES3057657T3 (fr)
IL (2) IL327175A (fr)
MA (1) MA53817A (fr)
MX (1) MX2021003606A (fr)
WO (1) WO2020072814A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019530713A (ja) 2016-10-13 2019-10-24 レトロフィン， インコーポレイテッド 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
WO2022246200A1 (fr) * 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Méthodes de traitement de maladies ou de troubles rénaux
WO2022266370A1 (fr) * 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan pour le traitement de la fibrose pulmonaire idiopathique
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2001044239A2 (fr) 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides utilises comme doubles antagonistes des recepteurs de l'angiotensine et de l'endotheline
WO2010114801A1 (fr) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Formulation orale d'agonistes des récepteurs de l'endothéline et de l'angiotensine ii à base de diphénylsulfonamide pour traiter une pression sanguine élevée et une néphropathie diabétique
WO2010135350A2 (fr) 2009-05-20 2010-11-25 Pharmacopeia, Llc Composes intermediaires de biphenyle et procedes pour la preparation d'un double antagoniste de recepteur d'angiotensine ii et d'endotheline
US9719981B2 (en) 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
US10744178B2 (en) * 2014-08-21 2020-08-18 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of disease
CN109982718A (zh) * 2016-09-19 2019-07-05 阿托恩波罗斯生命科学 基于环糊精的聚合物、方法、组合物及其应用
JP2019530713A (ja) * 2016-10-13 2019-10-24 レトロフィン， インコーポレイテッド 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
BR112021012226A2 (pt) 2018-12-21 2021-09-08 Travere Therapeutics, Inc. Composições de esparsentano amorfo

Also Published As

Publication number Publication date
CA3114434A1 (fr) 2020-04-09
MX2021003606A (es) 2021-08-16
ES3057657T3 (en) 2026-03-03
KR102902972B1 (ko) 2025-12-22
KR20210081338A (ko) 2021-07-01
AU2019354784A1 (en) 2021-04-15
US11207299B2 (en) 2021-12-28
IL281965B2 (en) 2026-08-01
AU2019354784B2 (en) 2025-07-10
EP3860594A1 (fr) 2021-08-11
JP2022514152A (ja) 2022-02-10
JP2024133735A (ja) 2024-10-02
IL281965A (en) 2021-05-31
US20200147050A1 (en) 2020-05-14
WO2020072814A1 (fr) 2020-04-09
BR112021006132A2 (pt) 2021-07-20
EP3860594B1 (fr) 2025-10-01
JP7524167B2 (ja) 2024-07-29
IL281965B1 (en) 2026-04-01
CN113286587A (zh) 2021-08-20
IL327175A (en) 2026-05-01

Similar Documents

Publication Publication Date Title
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MA55974A (fr) Composés triaryles pour le traitement de maladies pd-l1
EP3411380A4 (fr) Composés destinés au traitement de troubles ou de maladies oculaires
MA52003A (fr) Procédés de traitement de maladies associées au hpv
EP4045037C0 (fr) Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3866781A4 (fr) Nouvelles compositions pour le traitement de maladies inflammatoires
EP3890725A4 (fr) Compositions pour traiter des maladies dermatologiques
EP3621973A4 (fr) Composés pour la prévention et le traitement de maladies et leur utilisation
MA41841A (fr) Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
EP3273955A4 (fr) Traitement de maladies respiratoires
MA49141A (fr) Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
EP3866777A4 (fr) Polythérapie pour le traitement de maladies inflammatoires
MA53127A (fr) Utilisation de stimulateurs gcs pour le traitement de maladies mitochondriales
EP3877382A4 (fr) Nouveaux composés pour le traitement de maladies respiratoires
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
EP3866779A4 (fr) Traitement de maladies neurologiques
EP3593803A4 (fr) Composés destinés au traitement de maladies causées par l'accumulation d'oxalate
EP3737363A4 (fr) Méthodes de traitement de maladies inflammatoires chroniques
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3413898A4 (fr) Utilisation de tréhalose pour le traitement de maladies neurologiques